News

01.03.2018
Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished...

22.01.2018
Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication of fina...

Since its establishment over 30 years ago, Octapharma has grown into a truly global company providing life enhancing therapies to patients in over 100 countries. To find your local Octapharma office, access our global locations map

“As a world-wide provider of human proteins as treatments in immunotherapy, haematology, and intensive care and emergency medicine, Octapharma is constantly investing in the renovation and modernisation of our plants.„

Wolfgang Marguerre
Chairman of the Board